Incyte Corp. buy marge
Start price
17.11.16
/
50%
€95.52
Target price
18.09.17
€135.30
Performance (%)
12.51%
End price
18.09.17
€107.47
Summary
This prediction ended on 18.09.17 with a price of €107.47. The prediction had a final performance of 12.51%. marge has a follow-up prediction for Incyte Corp. where he still thinks Incyte Corp. is a Buy. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -0.661% | -0.661% | 46.852% | 20.195% |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% | 49.791% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% | 96.632% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% | 69.047% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% | 68.087% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)